London, United Kingdom
30 TECHNOLOGY, founded in 2018, is a pioneering biotechnology firm based in the United Kingdom. With a core mission encapsulated by their slogan, "Unlocking and delivering the promise of therapeutic Nitric Oxide," the company focuses on revolutionizing healthcare through the development of new models of care.
Their innovative approach aims at enhancing the body's natural healing and defense mechanisms, potentially addressing a spectrum of serious medical conditions. Operating primarily within the Biotechnology and Pharmaceutical sectors, 30 TECHNOLOGY positions itself at the intersection of cutting-edge scientific research and tangible patient outcomes.
As of now, the company has not disclosed any recent investment activities or investor participation, creating potential opportunities for venture capitalists seeking involvement in transformative healthcare innovations. With a robust platform centered on therapeutic Nitric Oxide, 30 TECHNOLOGY is primed for significant growth, attracting interest from stakeholders looking to support the next wave of biotechnological advancements.
